ESR1 and breast carcinoma: In the OPTION study, premenopausal patients with stage I–IIIB breast cancer with estrogen receptor-positive (ER+) and estrogen receptor-negative (ER−) tumors who were candidates for neoadjuvant or adjuvant chemotherapy were included.